151 related articles for article (PubMed ID: 16197449)
1. Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK.
Cheung CW; Burton C; Smith P; Linch DC; Hoskin PJ; Ardeshna KM
Br J Haematol; 2005 Oct; 131(2):193-200. PubMed ID: 16197449
[TBL] [Abstract][Full Text] [Related]
2. Central nervous system disease in hematologic malignancies: historical perspective and practical applications.
Pui CH; Thiel E
Semin Oncol; 2009 Aug; 36(4 Suppl 2):S2-S16. PubMed ID: 19660680
[TBL] [Abstract][Full Text] [Related]
3. CNS prophylaxis and treatment in non-Hodgkin's lymphoma: variation in practice and lessons from the literature.
Buckstein R; Lim W; Franssen E; Imrie KL
Leuk Lymphoma; 2003 Jun; 44(6):955-62. PubMed ID: 12854893
[TBL] [Abstract][Full Text] [Related]
4. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis.
Sancho JM; Ribera JM; Oriol A; Hernandez-Rivas JM; Rivas C; Bethencourt C; Parody R; Deben G; Bello JL; Feliu E;
Cancer; 2006 Jun; 106(12):2540-6. PubMed ID: 16700036
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.
Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
Cancer; 2002 Aug; 95(3):576-80. PubMed ID: 12209750
[TBL] [Abstract][Full Text] [Related]
6. The risk of CNS involvement in aggressive lymphomas in the rituximab era.
Benevolo G; Chiappella A; Vitolo U
Expert Rev Hematol; 2013 Dec; 6(6):643-52. PubMed ID: 24168678
[TBL] [Abstract][Full Text] [Related]
7. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
Ferreri AJ; Bruno-Ventre M; Donadoni G; Ponzoni M; Citterio G; Foppoli M; Vignati A; Scarfò L; Sassone M; Govi S; Caligaris-Cappio F
Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
[TBL] [Abstract][Full Text] [Related]
8. Central nervous system-directed preventative therapy in adults with lymphoma.
McMillan A
Br J Haematol; 2005 Oct; 131(1):13-21. PubMed ID: 16173958
[TBL] [Abstract][Full Text] [Related]
9. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma.
Chua SL; Seymour JF; Streater J; Wolf MM; Januszewicz EH; Prince HM
Leuk Lymphoma; 2002 Sep; 43(9):1783-8. PubMed ID: 12685832
[TBL] [Abstract][Full Text] [Related]
10. Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis.
Laskin JJ; Savage KJ; Voss N; Gascoyne RD; Connors JM
Leuk Lymphoma; 2005 Dec; 46(12):1721-7. PubMed ID: 16263574
[TBL] [Abstract][Full Text] [Related]
11. Secondary central nervous system lymphoma: risk factors and prophylaxis.
Montoto S; Lister TA
Hematol Oncol Clin North Am; 2005 Aug; 19(4):751-63, viii. PubMed ID: 16083835
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
13. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.
Kumar A; Vanderplas A; LaCasce AS; Rodriguez MA; Crosby AL; Lepisto E; Czuczman MS; Nademanee A; Niland J; Gordon LI; Millenson M; Zelenetz AD; Friedberg JW; Abel GA
Cancer; 2012 Jun; 118(11):2944-51. PubMed ID: 22006274
[TBL] [Abstract][Full Text] [Related]
14. [Treatment strategy for central nervous system involvement in intravascular large B-cell lymphoma].
Shimada K
Brain Nerve; 2011 May; 63(5):467-72. PubMed ID: 21515926
[TBL] [Abstract][Full Text] [Related]
15. Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more.
Herrlinger U; Glantz M; Schlegel U; Gisselbrecht C; Cavalli F
Semin Oncol; 2009 Aug; 36(4 Suppl 2):S25-34. PubMed ID: 19660681
[TBL] [Abstract][Full Text] [Related]
16. Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment.
van Besien K; Gisselbrecht C; Pfreundschuh M; Zucca E
Leuk Lymphoma; 2008; 49 Suppl 1():52-8. PubMed ID: 18821433
[TBL] [Abstract][Full Text] [Related]
17. [Late sequelae of central nervous system prophylaxis in children with acute lymphoblastic leukemia: high doses of intravenous methotrexate versus radiotherapy of the central nervous system--review of literature].
Zając-Spychała O; Wachowiak J
Med Wieku Rozwoj; 2012; 16(2):128-37. PubMed ID: 22971657
[TBL] [Abstract][Full Text] [Related]
18. Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when?
Cheah CY; Seymour JF
Curr Oncol Rep; 2015 Jun; 17(6):25. PubMed ID: 25912004
[TBL] [Abstract][Full Text] [Related]
19. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.
Vitolo U; Chiappella A; Ferreri AJ; Martelli M; Baldi I; Balzarotti M; Bottelli C; Conconi A; Gomez H; Lopez-Guillermo A; Martinelli G; Merli F; Novero D; Orsucci L; Pavone V; Ricardi U; Storti S; Gospodarowicz MK; Cavalli F; Sarris AH; Zucca E
J Clin Oncol; 2011 Jul; 29(20):2766-72. PubMed ID: 21646602
[TBL] [Abstract][Full Text] [Related]
20. CNS prophylaxis in lymphoma: who to target and what therapy to use.
Hill QA; Owen RG
Blood Rev; 2006 Nov; 20(6):319-32. PubMed ID: 16884838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
